ERBB2 and breast cancer: Finally, we selected a subset of patients with HER2+ breast cancer and neoadjuvant systemic treatment and found no difference in OS (p = 0.4622, n = 77 patients), RFS (p = 0.4661, n = 90 patients), and DFMS (p = 0.074, n = 49 patients).